Journal of Pharmaceutics

Research Article

Quantification of Lumefantrine in Human Plasma Using LC-MS/MS and Its Application to a Bioequivalence Study

Table 3

Stability results for lumefantrine ().


Stability	Level		% CV		% CV	% Change

Autosampler (34 h, 10°C)	LQC	633.33	3.38	605.19	4.77	−4.44
Autosampler (34 h, 10°C)	HQC	15829.36	1.40	15232.73	1.93	−3.77
Bench top (17 h at room temp.)	LQC	633.33	3.38	600.27	1.51	−5.22
Bench top (17 h at room temp.)	HQC	15829.37	1.40	15292.07	3.51	−3.38
Coolant (26 h, −70°C)	LQC	633.33	3.38	622.32	3.91	−1.74
Coolant (26 h, −70°C)	HQC	15829.37	1.40	15514.03	1.58	−1.99
Reinjection (29 h, 2–8°C)	LQC	555.86	4.90	575.11	5.28	3.46
Reinjection (29 h, 2–8°C)	HQC	16044.53	2.95	15570.59	2.52	−2.95
3rd freeze-thaw cycle (−70°C)	LQC	578.49	6.01	581.93	9.99	−0.59
3rd freeze-thaw cycle (−70°C)	HQC	14834.03	6.68	16427.64	4.79	10.74
Long term (221 days, −70°C)	LQC	555.86	4.90	578.54	3.67	4.08
Long term (221 days, −70°C)	HQC	16044.53	2.95	17745.02	3.86	10.60

: mean value of comparison samples (original concentrations before storage) concentrations (ng/mL); : mean value of stability samples (measured concentration after storage) concentrations (ng/mL); CV: coefficient of variation; h: hours, temp: temperature.